Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.
The DOI matches its Crossref record.
Abstract
PURPOSE: This phase II study was designed to assess the effects of mitoxantrone with prednisone in patients with metastatic prostate cancer who had progressed on hormonal therapy. The methods of assessment included quality-of-life analyses, pain indices, analgesic scores, and the National Prostatic Cancer Project (NPCP) criteria. PATIENTS AND METHODS: Patients received mitoxantrone 12 mg/m2 intravenously every 3 weeks plus prednisone 10 mg orally daily. All had a castrate serum testosterone and Eastern Cooperation Oncology Group (ECOG) performance status < or = 3, and had not received prior chemotherapy. Every 3 weeks, analgesic intake was scored, and a present pain intensity (PPI) record and visual analog scale (VAS) describing pain were collected. Every 6 weeks, the European Organization for Research and Treatment of Cancer (EORTC) core quality-of-life questionnaire plus a prostate-specific module were completed. A palliative response was defined as a decrease in analgesic score by > or = 50% or a decrease in PPI by > or = two integers without any increase in the other. RESULTS: Twenty-seven patients were entered onto the study. Nine of 25 (36%) assessable patients achieved a palliative response maintained for > or = two cycles (range, two to eight or more). Improvements in mean PPI and VAS pain scores after each cycle of therapy (P < .05) were seen. Quality-of-life analysis showed improvements in social and emotional functioning, and in pain and anorexia. Using NPCP criteria, one patient achieved a partial response (PR) and 12 had stable disease; one of seven patients with measurable disease had a PR. No serious nonhematologic toxicity was experienced, and there were no episodes of febrile neutropenia. CONCLUSION: Mitoxantrone with low-dose prednisone is a well-tolerated treatment regimen that has some beneficial effects on disease-related symptoms and quality of life for patients with advanced prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Validity of four pain intensity rating scales
Ferreira-Valente, M. A., Pais-Ribeiro, J. L., & Jensen, M. P. (2011) · Pain · doi:10.1016/j.pain.2011.07.005 · Cited by 1,872
“This is consistent with previous studies demonstrating the superiority of VAS and NRS responsiveness, due perhaps to the larger number of response levels that these 2 scales provide [6,9,41,50,55].”
ResultTannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,580
Self-citationCella, D., Eton, D. T., Lai, J.-S., Peterman, A. H., & Merkel, D. E. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00529-8 · Cited by 808
Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997) · Urology · doi:10.1016/s0090-4295(97)00459-7 · Cited by 696
The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30
King, M. T. (1996) · Quality of Life Research · doi:10.1007/bf00439229 · Cited by 666
Metadata
- Authors
- Moore, M. J., Osoba, D., Murphy, K., Tannock, I. F., Armitage, A., Findlay, B., Coppin, C., Neville, A., Venner, P., & Wilson, J.
- Venue
- Journal of Clinical Oncology
- Published
- 1994-04
- Volume
- 12
- Issue
- 4
- Pages
- 689-694
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1951802477
- Cited by
- 160
- References
- 0
- FWCI
- 8.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. https://app.cochat.ai/papers/10.1200/jco.1994.12.4.689
- The paper
- Moore, M. J., Osoba, D., Murphy, K., Tannock, I. F., Armitage, A., Findlay, B., Coppin, C., Neville, A., Venner, P., & Wilson, J. (1994). Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1994.12.4.689
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.